Semaglutide alters gut microbiota and improves NAFLD in db/db mice
Biochemical and Biophysical Research Communications · 2024-05 · 710 · 149882
DOI: 10.1016/j.bbrc.2024.149882 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2024-05. Verfasst von Tuohua Mao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Renmin Hospital of Wuhan University, Wuhan, 430060, PR China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2, Gastrointestinal Microbiome, Glucagon-Like Peptides. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease associated with type 2 diabetes mellitus (T2D). NAFLD can progress to nonalcoholic steatohepatitis (NASH), cirrhosis, and even cancer, all of which have a very poor prognosis. Semaglutide, a novel glucagon-like peptide-1 (GLP-1) receptor agonist, has been recognized as a specific drug for the treatment of diabetes. In this study, we used a gene mutation mouse model (db/db mice) to investigate the potential liver-improving effects of semaglutide. The results showed that semaglutide improved lipid levels and glucose metabolism in db/db mice. HE staining and oil red staining showed alleviation of liver damage and reduction of hepatic lipid deposition after injection of semaglutide. In addition, semaglutide also improved the integrity of gut barrier and altered gut microbiota, especially Alloprevotella, Alistpes, Ligilactobacillus and Lactobacillus. In summary, our findings validate that semaglutide induces modifications in the composition of the gut microbiota and ameliorates NAFLD, positioning it as a promising therapeutic candidate for addressing hepatic steatosis and associated inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Renmin Hospital of Wuhan University, Wuhan, 430060, PR China.
- Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, PR China.
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, 430060, PR China.
- Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, PR China. Electronic address: liman192@whu.edu.cn.
- Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, PR China. Electronic address: yogaqq116@whu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Mao, T., Zhang, C., Yang, S., Bi, Y., Li, M., & Yu, J. (2024). Semaglutide alters gut microbiota and improves NAFLD in db/db mice. Biochemical and Biophysical Research Communications, 710, 149882. https://doi.org/10.1016/j.bbrc.2024.149882
Vancouver
Mao T, Zhang C, Yang S, Bi Y, Li M, Yu J. Semaglutide alters gut microbiota and improves NAFLD in db/db mice. Biochemical and Biophysical Research Communications. 2024;710:149882. doi:10.1016/j.bbrc.2024.149882
BibTeX
@article{Mao2024,
author = {Mao, Tuohua and Zhang, Chenxuan and Yang, Shuang and Bi, Yingying and Li, Man and Yu, Jia},
title = {Semaglutide alters gut microbiota and improves NAFLD in db/db mice},
journal = {Biochemical and Biophysical Research Communications},
year = {2024},
volume = {710},
pages = {149882},
doi = {10.1016/j.bbrc.2024.149882}
}
EUVIMED